![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24485-24489, August 27, 1999
From the Department of Chemistry, The Pennsylvania State
University, University Park, Pennsylvania 16802
The location of the interaction of the COOH
terminus of the bacteriophage T4 DNA polymerase with its trimeric,
circular sliding clamp has been established. A peptide corresponding to
the COOH terminus of the DNA polymerase was labeled with a fluorophore and fluorescence spectroscopy used to show that it forms a specific complex with the sliding clamp by virtue of its low
KD value (7.1 ± 1.0 µM). The
same peptide was labeled with a photoaffinity probe and cross-linked to
the sliding clamp. Mass spectrometry of tryptic digests determined the
sole linkage point to be Ala-159 on the sliding clamp, an amino acid
that lies on the subunit interface. These results demonstrate that the
COOH terminus of the DNA polymerase is inserted into the subunit
interface of its sliding clamp, thereby conferring processivity to the
DNA polymerase.
Multiprotein complexes lie at the heart of DNA replication. In
bacteriophage T4, the DNA polymerase (gp43), its processivity factor or
sliding clamp (gp45), and the clamp-loader (gp44/62) form the
holoenzyme that is loaded onto DNA in a multistep process requiring
hydrolysis of ATP (1-3). gp44/62 (a 4:1 complex of gp44 and gp62) is
only a transient species in the holoenzyme assembly process,
hydrolyzing ATP to load gp45 onto DNA and then chaperoning gp43 onto
the gp45/DNA complex (4). Likewise, the intermediate states of assembly
are distinct and transient (3, 5). The x-ray crystal structures of gp45
from bacteriophage T41 and
gp43 from bacteriophage RB69 (63% identity with gp43 from T4 (6)) are
known (7), but the precise relative orientations of the proteins during
and after the holoenzyme assembly process are unknown. X-ray
crystallography should be able to eventually determine the structures
of stable multiprotein complexes such as the final holoenzyme
structure, but other methods will be required to determine the
structures of transient or unstable structures during the holoenzyme
assembly process. We have chosen to use fluorescence spectroscopy and
mass spectrometry to map the connection point between the COOH terminus
of gp43 and gp45, the interaction that is at the core of the holoenzyme
and confers processivity to gp43 (8).
We have shown previously that the COOH terminus of gp43 is essential
for forming the holoenzyme, and a peptide corresponding to the COOH
terminus of gp43 inhibits the interaction of gp45 and gp44/62, thereby
inhibiting formation of the holoenzyme (8). The importance of the COOH
terminus of gp43 was also investigated by others (9). Additionally, the
COOH termini of gp33 and gp55 have been shown to be essential for
interaction with gp45 (10). gp33 is a transcriptional co-activator
(11), and gp55 is a In this study, Peptide 1 was labeled with the fluorophore
IAEDANS2 or the photoaffinity
probe TFPAM-3 (see Fig. 1) to investigate the interaction point on
gp45. The peptide 1-IAEDANS conjugate was shown to interact with gp45
in a 1:1 complex (peptide:gp45 monomer) with micromolar affinity,
suggesting a specific interaction. The peptide 1-TFPAM-3 conjugate was
cross-linked to gp45, which was then digested with trypsin and the
resultant peptides separated by HPLC and analyzed by mass spectrometry.
We have found that the COOH-terminal peptide of gp43 cross-links to
Ala-1593 of gp45, an amino
acid that sits at the subunit interface of gp45, confirming that the
COOH terminus of gp43 is inserted into the gp45 subunit interface to
form the topological link between gp43 and the DNA template.
Materials and Their Sources--
Peptide 1 was a generous gift
of Michael Moore of SmithKline Beecham. IAEDANS and TFPAM-3 were from
Molecular Probes (Eugene, OR). Trifluoroacetic acid (HPLC grade) was
from J. T. Baker (Phillipsburg, NJ). Trypsin
(L-1-tosylamide-2-phenylethyl chloromethyl ketone-treated) was from U. S. Biochemical Corp. The MALDI matrix
Peptide Labeling--
To form the peptide 1-IAEDANS conjugate, 1 mg of peptide 1 was dissolved in 500 µl of 50 mM HEPES,
pH 7.6, 150 mM potassium acetate, 1 mM EDTA,
and 10% glycerol (labeling buffer) and mixed with 5 mg of IAEDANS
dissolved in 500 µl of labeling buffer. The mixture was nutated in
the dark at 4 °C for 12 h and then purified by HPLC on a
4.6 × 250-mm C18 column (Vydac, Hesperia, CA) using the following
gradient at 1 ml min Protein--
gp45 was purified as described previously (18) and
quantitated using a Bradford protein assay (Bio-Rad).
Fluorescence--
Fluorescence measurements were performed on a
SLM-8000C spectrofluorimeter (SLM Instruments, Urbana, IL). gp45 and
peptide 1-IAEDANS in 25 mM Tris acetate, pH 7.5, 150 mM potassium acetate, 10 mM magnesium acetate,
and 10 mM Photocross-linking and Tryptic Digests--
gp45 was dialyzed
versus 30 mM HEPES, pH 7.0, 50 mM
NaCl, and 1 mM EDTA to remove DTT added for protein
storage. This protein (10 µM) and 150 µM
peptide 1-TFPAM-3 were mixed in 20 mM Tris, pH 7.5, 150 mM potassium acetate, and 10 mM magnesium
acetate and split into 20-µl aliquots in microcentrifuge tubes.
Photolysis was carried out using a Spectroline (Westbury, NY) model
XX-15B lamp at 25 °C at a distance of 6 cm for 15 min. Aliquots
(typically 20) were recombined and the buffer changed to 0.1 M ammonium bicarbonate using a Centricon-10 (Amicon,
Bevery, MA) concentrator with a molecular mass cutoff of 10,000 Da.
This procedure removed most of the unreacted, photolyzed peptide. To
this solution (200 µl) were added 25 µl of 1 mg/ml trypsin in water
and incubated at 37 °C for 18 h. Tryptic peptides were
separated by HPLC on a C18 column using the above gradient for
purification of the peptide 1-TFAPM-3 conjugate. Peaks were collected,
dried under vacuum, and subjected to analysis by mass spectrometry as
described below.
Mass Spectrometry--
MALDI mass spectra of desalted tryptic
digests and individual HPLC peaks were obtained on a Voyager-DE STR
mass spectrometer (PerSeptive Biosystems, Framingham, MA) using a
nitrogen laser (337 nm) and Molecular Modeling--
The model of the holoenzyme depicted in
Fig. 5 was made from the individual x-ray crystal structures of
bacteriophage RB69 gp43 (7) and bacteriophage T4 gp451
using Quanta (version 97, Molecular Simulations, San Diego, CA) running
on a Silicon Graphics Indigo2 (Mountain View, CA) workstation.
We recently determined that the COOH terminus of gp43 is critical
for forming the bacteriophage T4 holoenzyme (8). The COOH terminus of
gp43 shares homology with the COOH termini of gp33 and gp55 (see Fig.
1), proteins that also have been shown to
interact with gp45 through their COOH termini (10). We have determined
the contact point of gp45 on the COOH terminus of gp43 using
fluorescence spectroscopy and mass spectrometry.
Fluorescence--
An eight-amino acid peptide (Peptide
1, see Fig. 1) corresponding to the seven COOH-terminal amino
acids of gp43 and an NH2-terminal cysteine was labeled with
the fluorophore IAEDANS (Fig. 1). Titration with gp45 (constant peptide
concentration) resulted in a FRET signal to IAEDANS at 485 nm upon
exciting gp45 tryptophans at 280 nm (Fig.
2). Likewise, titration with peptide
(constant gp45 concentration) resulted in gp45 tryptophan quenching at
340 nm upon exciting at 280 nm (Fig. 2). These fluorescence titrations were fit to an average KD value of 7.1 ± 1.0 µM (8.2 ± 0.4 µM and 6.1 ± 0.5 µM for titrating peptide and gp45, respectively). To fit
both curves successfully with the same KD value, the
gp45 concentration had to be in terms of monomers rather than trimers,
suggesting that there are three peptide binding sites per gp45 trimer.
The absence of sigmoidal character indicates the absence of cooperative
binding and the low KD value suggests a specific
interaction.
Photocross-linking--
Peptide 1 was modified with a
photoaffinity probe to determine the interaction point of the COOH
terminus of gp43 on gp45. Several photoaffinity probes were tested for
their ability to form photocross-links between peptide 1 and gp45.
Derivitizing the NH2 terminus of peptide 1 with an
arylazide resulted in quenching of the photoactivated azide by the
neighboring free thiol of cysteine. Derivitizing the cysteine thiol
with a standard arylazide resulted in a low yield of photocross-links,
while the perfluoroarylazide TFPAM-3 (Fig. 1) gave the highest yield of
cross-links. Following UV irradiation of gp45 and peptide 1-TFPAM-3,
cross-linked gp45 showed a slight decrease in mobility by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. Using 15 equivalents of peptide per gp45 trimer, about 50% of gp45 was shifted
to this new band (data not shown). Unreacted, photolyzed peptide was
almost completely removed by ultrafiltration and the mixture of
cross-linked and uncross-linked gp45 was digested with trypsin. HPLC
separation of the tryptic digest yielded about 20 peaks, including
several late-eluting peaks that did not appear in a
mock-photocross-linking reaction with gp45 but without peptide
1-TFPAM-3. All peaks were collected and subject to analysis by mass spectrometry.
Mass Spectrometry--
The identities of the tryptic peptides were
initially confirmed by MALDI-MS. The majority of possible tryptic
fragments of gp45 were identified (13 of 21) as well as two tryptic
fragments due to one missed tryptic cleavage. The eight tryptic
fragments that were not observed were predicted to be less than 500 or
greater than 5000 Da. The late eluting peaks not observed in the
mock-photocross-linking reaction were assigned to the photolysis
products of peptide 1-TFPAM-3, which did not react with gp45, or
unphotolyzed peptide 1-TPFAM-3. These species were not completely
removed by ultrafiltration before treatment with trypsin. One HPLC peak
(20.5 min) was found to contain two tryptic fragments of gp45 as well
as a fragment that did not have a mass corresponding to a tryptic
fragment of gp45 or a fragment missing one or more predicted tryptic
cleavages. This fragment, m/z 2362 (Fig.
3), corresponds to the mass of the gp45
tryptic fragment from amino acids 155-1643 plus the mass
of peptide 1-TFPAM-3 expected following photolysis. The specificity of
product formation leads us to conclude that this tryptic fragment of
gp45 lies at the subunit interface. The fragment has one missed
cleavage at Arg-162 and is 1 Da higher in mass than expected.
Exact-mass MALDI-MS using internal calibration standards confirmed the
mass assignment (data not shown). We speculate that Arg-162 may have
been oxidatively converted to citruline during the photocross-linking
process. This would add one mass unit to the total mass of the product
and prevent cleavage by trypsin at this amino acid.
The 20.5-min HPLC peak was subjected to post-source decay in the MALDI
using an ion gate set to allow input of ions m/z
2362 ± 50 in order to confirm the identity and structure of the
cross-linked product and determine the exact linkage point of the
photocross-linker. Fig. 4 shows the
assigned structure of the cross-linked product as well as several
diagnostic fragment ions from the post-source decay experiment. The
only amino acid in the 155-164 tryptic fragment that remains attached
to the photocross-linking moiety in all ion fragments is Ala-159. These
ion fragments therefore allow us to assign the sole linkage point of
the photocross-linker as Ala-159, as shown in Fig. 4. All of the ion
fragments are also consistent with the predicted amino acid
sequence of the 155-164 gp45 tryptic fragment.
DNA replication and late RNA transcription in bacteriophage T4
both require the coordination of several proteins to form processive complexes. The role of gp45 is central in these processes, providing a
topological link between proteins and nucleic acid. Defining the exact
mode of interaction between the individual proteins in these complexes
will further the understanding of the structure and function of these
multiprotein complexes.
The COOH termini of gp43 (8), as well as gp33 and gp55 (10), have been
shown previously to be essential for interaction with gp45. The motif
(S/T)LDFL is found at the COOH termini of all three of these proteins
(see Fig. 1) and suggests a common mode of interaction with gp45. We
previously employed a mutant of gp43 lacking the last six COOH-terminal
amino acids and found that this mutant could not be assembled into a
holoenzyme complex. Peptide 1 was shown to be a competitive inhibitor
of the ATPase activity of gp44/62 in the presence of gp45 with a
Ki of 1.6 µM (expressed as a function
of gp45 trimers; multiply by 3 to compare with KD
below), thereby inhibiting the formation of the holoenzyme (8). The
peptide 1-IAEDANS conjugate was found to have a Ki
of 2.9 µM (expressed as a function of gp45 trimers; data
not shown), indicating that modification of peptide 1 at the terminal
cysteine does not significantly alter its ability to disrupt the
interaction between gp44/62 and gp45.
We have confirmed the specific interaction of peptide 1 with gp45 by
fluorescence titration. Peptide 1 was labeled with the fluorophore
IAEDANS, and both FRET from gp45 tryptophans to IAEDANS and gp45
tryptophan quenching by IAEDANS were observed (see Fig. 2). The
stoichiometry of the peptide-gp45 interaction was found to be one
peptide to one gp45 monomer, since gp45 concentrations had to be
expressed as a function of monomers to obtain the same KD value (7.1 ± 1.0 µM) for both
titrations. The low KD value, as well as the low
Ki value, suggest that the peptide is making a
specific interaction with gp45. The presence of a specific interaction
improves the chances that photocross-linking will occur at
predominantly one site and thereby improves the odds that the
photocross-linked product will be found and characterized.
It is unlikely in vivo or in vitro that three
gp43 molecules bind to one gp45 molecule, however. In the model of the
holoenzyme shown in Fig. 5, there is not
enough room for even two gp43 molecules to bind on the same face of
gp45 (gp43 interacts with gp45 on only one face of gp45 (19)), and the
stoichiometry of gp43 and gp45 in the holoenzyme has been shown to be
1:1 (20). The small size of the peptide probably causes each gp45
subunit interface to behave as if isolated from the other two. The
absence of sigmoidal character in the binding curves is supportive of
the gp45 subunit interfaces binding the peptide without
cooperativity.
The Carboxyl Terminus of the Bacteriophage T4 DNA Polymerase
Contacts Its Sliding Clamp at the Subunit Interface*
, and
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-family protein (12), and their interaction with
gp45 is required in late RNA transcription (13). The sequences of the
COOH termini of gp33, gp55, and gp43, as well as the sequence of the
COOH-terminal peptide of gp43 (peptide 1), are shown in Fig. 1. These
three proteins have a common (S/T)LDFL motif, suggesting a shared mode of interaction with gp45. gp45 has shown to be a circular trimer by
x-ray crystallography, with an internal hole large enough to accommodate DNA. We have recently found that the trimer is open in
solution and have speculated that the COOH-terminal tail of gp43 would
be inserted into the open subunit interface of gp45 during holoenzyme
assembly (14).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-cyano-4-hydroxycinnamic acid was from Sigma. All other materials
were of analytical grade or better.
1: solvent A, 0.1% trifluoroacetic
acid in H2O; solvent B, 0.1% trifluoroacetic acid in
CH3CN; the column was equilibrated with 80% solvent A, and
350 µl of the above mixture was injected and the column maintained at
the initial conditions until stabilization of the baseline. The peptide
was eluted with a linear 13-min gradient from 80 to 54% solvent A. The
fraction containing the peptide conjugate was dried under vacuum,
redissolved in water, and quantitated using 5660 M
1 cm
1 as the extinction
coefficient of the probe at 336 nm. To form the peptide 1-TFPAM-3
conjugate, 0.5 mg of peptide 1 were dissolved in 500 µl of labeling
buffer and mixed with 1 µl of 1 M dithiothreitol to
reduce any intermolecular disulfides. TFPAM-3 (1 mg) was dissolved in
200 µl of dimethyl sulfoxide and added to the above mixture. After
incubation in the dark on ice for 1 h, the conjugate was purified
by HPLC on a 4.6 × 250-mm C18 column (Vydac) using the following
gradient at 1 ml min
1: solvent A, 0.1% trifluoroacetic
acid in H2O; solvent B, 0.1% trifluoroacetic acid in
CH3CN; 100% solvent A for 2 min, a 20-min linear gradient
from 100 to 50% solvent A, and a 5-min linear gradient from 50 to 0%
solvent A. The peptide 1-TFPAM-3 conjugate was collected at 25 min,
dried under vacuum, redissolved in 50 mM Tris, pH 7.5, and
quantitated using 14,000 M
1 cm
1
as the extinction coefficient of the probe at 250 nm. Modification was
confirmed by MALDI-MS ([M + H]+ m/z
1272.8, calculated 1272.5).
-mercaptoethanol were excited at 280 nm and
FRET observed at 485 nm (titrating in gp45) or tryptophan quenching
observed at 340 nm (titrating in peptide 1-IAEDANS). Binding data were
fit to the equation Fobs = Fo
(T ×
F/(T + KD)), where Fobs is observed
fluorescence, Fo is initial fluorescence,
T is the concentration of the compound (gp45 or peptide
1-IAEDANS) that was titrated into the solution, and
F is
the change in observed fluorescence from initial fluorescence. Data
were fit using KaleidaGraph (Synergy Software, Reading, PA) to
determine KD.
-cyano-4-hydroxycinnamic acid as a
matrix. Nominal mass assignments were made using linear mode operation,
and more accurate assignments (approximately ± 10 ppm) were
obtained by addition of internal standard peptides and analysis in
reflector mode. Post-source decay spectra were obtained using the
addition of nitrogen as a collision gas (1.3 × 10
6
mm Hg measured at the ion gauge).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (22K):
[in a new window]
Fig. 1.
Sequence alignments of the COOH termini of
gp43, gp33, and gp55. The shared (S/T)LDFL motif is shown in
bold. The sequence of peptide 1 and the structures of
IAEDANS and TFPAM-3 are also shown.

View larger version (14K):
[in a new window]
Fig. 2.
Fluorescence titration of gp45 and peptide 1 labeled with IAEDANS. Relative fluorescence is plotted
versus the concentration of the added component.
Circles, peptide 1-IAEDANS was titrated into a 100 nM solution of gp45. gp45 tryptophans were excited at 280 nm and tryptophan emission followed at 340 nm. Squares, gp45
was titrated into a 100 nM solution of peptide 1-IAEDANS.
gp45 tryptophans were excited at 280 nm and FRET to IAEDANS observed at
485 nm. For both titrations, relative fluorescence values were
corrected for the dilution factor and for the residual fluorescence of
the added component. Fitting the data to the equation
Fobs = Fo
(T ×
F/(T + KD)), where
Fobs is observed fluorescence,
Fo is initial fluorescence, T is the
concentration of the titrated compound, and
F is the
change in observed fluorescence from initial fluorescence (solid
lines), yields KD values of 8.2 ± 0.4 µM (circles) and 6.1 ± 0.5 µM (squares).

View larger version (17K):
[in a new window]
Fig. 3.
MALDI mass spectrum of the 20.5-min HPLC peak
from the tryptic digest of cross-linked gp45. gp45 and
peptide 1-TFPAM-3 were cross-linked by exposure to UV light,
uncross-linked TFPAM-3 removed by ultrafiltration, and
cross-linked gp45 digested with trypsin. Tryptic fragments were
separated by HPLC, and the 20.5-min peak was collected, dried under
vacuum, and analyzed by MALDI-MS. Peptide molecules ionized by
attachment of H+, Na+, and K+ are
shown with resolution of natural isotope distributions. The
monoisotopic (no heavy atoms) [M + H]+ ion is observed at
m/z 2361.9 (theoretical 2362.1). Data were
acquired in reflector mode with mass assignments based on calibration
with a mixture of external standard peptides.

View larger version (21K):
[in a new window]
Fig. 4.
Structure of cross-linked product.
Diagnostic fragment ions observed in the post-source decay experiment
and their assigned cleavages are indicated.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (46K):
[in a new window]
Fig. 5.
Model of the holoenzyme using the
bacteriophage RB69 gp43 (left,
darker) and bacteriophage T4 gp45
(right, lighter) x-ray crystal
structures and B-form DNA. The COOH-terminal tail of gp43,
indicated with an arrow, has been inserted into the gp45
subunit interface.
The peptide 1-TFPAM-3 conjugate was found to cross-link to gp45 at Ala-159,3 an amino acid that lies at the gp45 subunit interface. Photocross-links were formed with an excess of peptide 1-TFPAM-3 to improve the yield of cross-links. A mixture of cross-linked and uncross-linked gp45 was digested with trypsin, the tryptic fragments separated by HPLC, and the identities of the tryptic fragments assigned by MALDI-MS analysis. Only one cross-linked fragment was found in the 20 HPLC peaks assayed: amino acids 155-164 connected to peptide 1-TFPAM-3 (see Fig. 4). This tryptic fragment has a missed cleavage at Arg-162 and the ion found, m/z 2362, is 1 mass unit higher than predicted. Oxidative damage of Arg-162 would prevent trypsin from cleaving at this amino acid, so we speculate that Arg-162 has been converted to citruline. Conversion of the charged guanidine moiety to the uncharged urea moiety adds 1 Da in mass. Citruline is the product of arginine oxidation by nitric-oxide synthetase (21), and the photocross-linking conditions (strong UV light and highly reactive nitrenes) would be conducive to generation of reactive oxygen species and oxidation of proteins.
The location of cross-linking, Ala-159, was determined from the identification of fragmentation ions using post-source decay in the MALDI instrument. Fig. 4 shows the assigned structure of the cross-linked product as well as several diagnostic fragment ions that allow us to confirm Ala-159 as the sole linkage point. The m/z 1719 fragment ion results from loss of LTRVK, the five amino acids neighboring on the COOH-terminal side of Ala-159, while the m/z 1931 fragment ion results from loss of VEDS, the four amino acids neighboring on the NH2-terminal side of Ala-159. All of the other ion fragments shown in Fig. 4 are fully consistent with the amino acid sequence of the cross-linked product (m/z 1814, 796, 624, and 244), and the m/z 1014 fragment ion is also diagnostic for the Ala-159 linkage point. Unfortunately, the resolution of the MALDI during post-source decay (empirically determined to be less than ±2 Da) does not allow us to unambiguously assign the Arg-162 oxidation to citruline. We are currently performing additional mass spectrometry experiments to characterize this oxidation. These experiments as well as the full details of the mass spectrometry experiments will be reported in a subsequent report.
Fig. 5 shows a model of the holoenzyme based on the x-ray crystal structures of bacteriophage RB69 gp43 (7) and bacteriophage T4 gp45.1 Threading the tail of gp43 through the subunit interface of gp45 and docking the two proteins against each other allows gp43 to contact predominantly two subunits of gp45. Determining the precise orientation of these other contacts will require additional experiments. gp33 and gp55, whose structures are unknown, likely interact with gp45 in a fashion similar to gp43, with their COOH termini inserted into the gp45 subunit interface, due to the homology of their COOH termini (see Fig. 1).
Conclusion--
The COOH terminus of gp43 has been shown by
fluorescence spectroscopy and mass spectrometry to be inserted into the
gp45 subunit interface. DNA replication and late RNA transcription
achieve their processivity by the interaction of the COOH termini of
gp43, gp33, and gp55 with the subunit interface of gp45, providing
substantial stabilization of the complexes by relatively short
stretches of amino acids. Photocross-linking and mass spectrometry
should prove to be powerful tools, providing insight into the
structures of transient multiprotein complexes.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Ismail Moarefi and John Kuriyan for providing the x-ray structure coordinates of gp45 before publication and Gary Latham, Ernesto Abel-Santos, and Michael Trakselis for helpful discussions.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants GM13306 (to S. J. B.) and GM19492 (to S. C. A.). The mass spectrometer was purchased in part with funds from National Institutes of Health Grant RR11318.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Current address: Laboratoire de Biochimie Physique et des
Biopolymères, Université Catholique de Louvain,
Bâtiment Lavoisier, 1/1B Place L. Pasteur, B-1348
Louvain-la-Neuve, Belgium.
§ To whom correspondence should be addressed. Tel.: 814-865-2882; Fax: 814-865-2973; E-mail: sjb1@psu.edu.
1 J. Kuriyan, personal communication.
3 The sequence of gp45 originally submitted to the GenBankTM data base under GenBankTM accession number M10160 (Sequence ID 215899; Ref. 15) was incorrect. Three changes (R92P, D99V, and L128V) and one insertion (Asp after Asp-69) were found by additional DNA sequencing, and the GenBankTM data base was subsequently updated under GenBankTM accession number M10160 (Sequence ID 2947028; Refs. 16 and 17). These mutations were confirmed in the present study by mass spectrometry. The insertion required a renumbering of the sequence after Asp-69. All the amino acids of gp45 are numbered in this manuscript taking the insertion and the revised GenBankTM data base entry into account.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: IAEDANS, 5-((((2-iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid; FRET, fluorescence-resonance energy transfer; HPLC, high-performance liquid chromatography; MALDI, matrix-assisted laser desorption ionization; MS, mass spectrometry; TFPAM-3, N-(4-azido-2,3,5,6-tetrafluorobenzyl)-3-maleimidopropionic acid.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Young, M. C., Reddy, M. K., and von Hippel, P. H. (1992) Biochemistry 31, 8675-8690[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Sexton, D. J., Berdis, A. J., and Benkovic, S. J. (1997) Curr. Opin. Chem. Biol. 1, 316-322 [CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Sexton, D. J., Kaboord, B. F., Berdis, A. J., Carver, T. C., and Benkovic, S. J. (1998) Biochemistry 37, 7749-7756[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Kaboord, B. F., and Benkovic, S. J. (1995) Curr. Biol. 5, 149-157[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Pietroni, P.,
Young, M. C.,
Latham, G. J.,
and von Hippel, P. H.
(1997)
J. Biol. Chem.
272,
31666-31676 |
| 6. |
Wang, C.-C.,
Yeh, L. S.,
and Karam, J. D.
(1995)
J. Biol. Chem.
270,
26558-26564 |
| 7. | Wang, J., Sattar, A. K. M. A., Wang, C.-C., Karam, J. D., Konigsberg, W. H., and Steitz, T. A. (1997) Cell 89, 1087-1099[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Berdis, A. J.,
Soumillion, P.,
and Benkovic, S. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
12822-12827 |
| 9. | Goodrich, L. D., Lin, T.-C., Spicer, E. K., Jones, C., and Konigsberg, W. H. (1997) Biochemistry 36, 10474-10481[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Sanders, G. M., Kassavetis, G. A., and Geiduschek, E. P. (1997) EMBO J. 16, 3124-3132[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Herendeen, D. R.,
Williams, K. P.,
Kassavetis, G. A.,
and Geiduschek, E. P.
(1990)
Science
248,
573-578 |
| 12. |
Kassavetis, G. A.,
and Geiduschek, E. P.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
5101-5105 |
| 13. |
Herendeen, D. R.,
Kassavetis, G. A.,
Barry, J.,
Alberts, B. M.,
and Geiduschek, E. P.
(1989)
Science
245,
952-958 |
| 14. | Alley, S. C., Shier, V. K., Abel-Santos, E., Sexton, D. J., Soumillion, P., and Benkovic, S. J. (1999) Biochemistry 38, 7696-7709[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Spicer, E. K.,
Noble, J. A.,
Nossal, N. G.,
Konigsberg, W. H.,
and Williams, K. R.
(1982)
J. Biol. Chem.
257,
8972-8979 |
| 16. | Latham, G. J. (1998) Res. Commun. Biochem. Cell. Mol. Biol. 2, 139-147 |
| 17. |
Yeh, L.-S.,
Hsu, T.,
and Karam, J. D.
(1998)
J. Bacteriol.
180,
2005-2013 |
| 18. |
Nossal, N. G.
(1979)
J. Biol. Chem.
254,
6026-6031 |
| 19. |
Latham, G. J.,
Bacheller, D. J.,
Pietroni, P.,
and von Hippel, P. H.
(1997)
J. Biol. Chem.
272,
31677-31684 |
| 20. | Berdis, A. J., and Benkovic, S. J. (1996) Biochemistry 35, 9253-9265[CrossRef][Medline] [Order article via Infotrieve] |
| 21. |
Marletta, M. A.
(1993)
J. Biol. Chem.
268,
12231-12234 |
This article has been cited by other articles:
![]() |
S. W. Nelson, J. Yang, and S. J. Benkovic Site-directed Mutations of T4 Helicase Loading Protein (gp59) Reveal Multiple Modes of DNA Polymerase Inhibition and the Mechanism of Unlocking by gp41 Helicase J. Biol. Chem., March 31, 2006; 281(13): 8697 - 8706. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Gangisetty, C. E. Jones, M. Bhagwat, and N. G. Nossal Maturation of Bacteriophage T4 Lagging Strand Fragments Depends on Interaction of T4 RNase H with T4 32 Protein Rather than the T4 Gene 45 Clamp J. Biol. Chem., April 1, 2005; 280(13): 12876 - 12887. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nechaev, M. Kamali-Moghaddam, E. Andre, J.-P. Leonetti, and E. P. Geiduschek The bacteriophage T4 late-transcription coactivator gp33 binds the flap domain of Escherichia coli RNA polymerase PNAS, December 14, 2004; 101(50): 17365 - 17370. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yang, Z. Zhuang, R. M. Roccasecca, M. A. Trakselis, and S. J. Benkovic From The Cover: The dynamic processivity of the T4 DNA polymerase during replication PNAS, June 1, 2004; 101(22): 8289 - 8294. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Trakselis, R. M. Roccasecca, J. Yang, A. M. Valentine, and S. J. Benkovic Dissociative Properties of the Proteins within the Bacteriophage T4 Replisome J. Biol. Chem., December 12, 2003; 278(50): 49839 - 49849. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Miller, E. Kutter, G. Mosig, F. Arisaka, T. Kunisawa, and W. Ruger Bacteriophage T4 Genome Microbiol. Mol. Biol. Rev., March 1, 2003; 67(1): 86 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Neely, A. H. Hassan, C. E. Brown, L. Howe, and J. L. Workman Transcription Activator Interactions with Multiple SWI/SNF Subunits Mol. Cell. Biol., March 15, 2002; 22(6): 1615 - 1625. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Alley, M. A. Trakselis, M. U. Mayer, F. T. Ishmael, A. D. Jones, and S. J. Benkovic Building a Replisome Solution Structure by Elucidation of Protein-Protein Interactions in the Bacteriophage T4 DNA Polymerase Holoenzyme J. Biol. Chem., October 12, 2001; 276(42): 39340 - 39349. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Trakselis, S. C. Alley, E. Abel-Santos, and S. J. Benkovic Creating a dynamic picture of the sliding clamp during T4 DNA polymerase holoenzyme assembly by using fluorescence resonance energy transfer PNAS, July 17, 2001; 98(15): 8368 - 8375. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |